NCT04089189 2026-01-28
SABRINA
Impact Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
4 trialsNCT06617923 2025-10-27
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07120451 2025-08-13
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Fudan University
Phase 2 Not yet recruiting
NCT03508011 2021-03-30
A Study of IMP4297 in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
Phase 1 Completed